Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 66Lung Neoplasms 26Small Cell Lung Carcinoma 10Pancreatic Neoplasms 6Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasm Metastasis 4Colorectal Neoplasms 4Carcinoma, Squamous Cell 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Ovarian Neoplasms 3Carcinoma, Pancreatic Ductal 3Adenocarcinoma of Lung 3Sarcoma 2Recurrence 2Rectal Neoplasms 2Prostatic Neoplasms 2NSCLC 2Melanoma 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma 2Tumor Virus Infections 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11aflutinib 9Drug Therapy 9Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NSCLC × Albumin-Bound Paclitaxel × Thoracic × Clear all
NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

EQRx International, Inc.

Phase 3 Terminated
8 enrolled 7 charts
Thoracic

NSCLC

NCT00874848 2016-11-29

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

HiberCell, Inc.

Phase 2 Completed
90 enrolled 20 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡